UP!

ENZN $0.46

ENZN target price
0.46
0
0
Enzon Pharmaceuticals, Inc
Type
Public
Traded as NASDAQ: ENZN
Industry Biotechnology
Founded 1981
Headquarters Piscataway, New Jersey, Piscataway, New Jersey, United States
Key people

George W. Hebard III, M.B.A. (CEO, Interim Principal Executive Officer, Interim Chief Operating Officer)

Richard L. Feinstein CPA
( Principal Financial Officer, Principal Accounting Officer) (Dec 31, 2012))
Products Drugs
Revenue $ 34.49M (Dec31, 2013)
Website enzon.com

Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.

George W. Hebard III, M.B.A. (CEO, Interim Principal Executive Officer, Interim Chief Operating Officer)

Enzon Pharmaceuticals, Inc started its earliest business in 1981. Now, the focus of the company is mainly on development and production of drugs for cancer patients with high unmet needs. It is also actively researching on improving the chemical attachment of PEG to help provide antibodies in molecules. In 2010, Enzon Pharmaceuticals, Inc.sold its specialty pharmaceutical business to the sigma-tau Group (sigma-tau).

The products of Enzon Pharmaceuticals, Inc include four principal compounds of different clinical development, as well as several novel mRNA antagonists in preclinical research.

In July 2012, Enzon Pharmaceuticals presented the result from pre-clinical studies about human interferon-beta-1b (IFN-β-1b) and an anti-TNF-α antibody fragment (Fab) through releasable PEGylation at the 39th Annual Meeting & Exposition of the Controlled Release Society.
In June 2012, Enzon Pharmaceuticals presented the Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors at the 2012 Advances in Neuroblastoma Research Conference. In the same month, the company presented the Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast at the American Society of Clinical Oncology Meeting.
In May 2012, Enzon Pharmaceuticals reached a strategic partnership using Enzon's PEGylation linker technology and PEG-SN38 (EZN-2208) in China.

The ticker symbol for Enzon Pharmaceuticals, Inc is "ENZN", which is traded on NASDAQ.

The company has recently launched a nationwide recall of OMONTYS injection because of reports on serious hypersensitivity reactions, including possible life-threatening anaphylaxis.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2010-05-05 Initiated C.K. Cooper Buy $18
2009-02-20 Reiterated Caris & Company Buy $14 to $13
2008-12-10 Initiated Caris & Company Buy $14
2008-09-10 Initiated Oppenheimer Outperform $14
2010-05-05 Initiated C.K. Cooper Buy $18
2009-02-20 Reiterated Caris & Company Buy $14 to $13
2008-12-10 Initiated Caris & Company Buy $14
2008-09-10 Initiated Oppenheimer Outperform $14

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ENZN 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
ICAHN CARL C 13.38%  (5904863) ARII / CVI / CVRR / ENZN / FDML / FRX / HAIN / HLF / HOLX / HTZ / IEP / LNG / MENT / NAV / NUAN / PBY / RNF / SD / TTWO / VGR / VLTC / WBMD / WCIC / XRX /
del Campo Ralph Chief Operating Officer 0.46%  (204633) ENZN /
TOOMAN CRAIG A Exec. V.P. Finance, CFO 0.36%  (160480) ENZN / PETX /
HORAK IVAN D EVP, R&D, CSO 0.31%  (138476) ENZN /
Davit Paul Stephen Exec. Vice Pres. HR 0.25%  (109314) ENZN /
Buchbinder Aby VP, Clinical Development 0.18%  (79246) ENZN /
Rackear Andrew D. VP and General Counsel 0.18%  (78019) ENZN /
Conover Charles SVP, R&D Program Management 0.17%  (74793) ENZN /
Stancic Ana Senior VP, Finance and CFO 0.16%  (70000) ENZN / IMNP /
SALISBURY ROBERT C 0.15%  (67707) ENZN /
DENNER ALEXANDER J 0.14%  (60620) APRI / ARIA / BIIB / ENZN / MDCO / MSTX / VVUS /
CLASSON ROLF A 0.13%  (55320) AUXL / CTLT / ENZN / HRC / PRGO /
MICATI VICTOR P 0.11%  (50625) ENZN /
Mulligan Richard 0.11%  (49064) BIIB / ENZN /
HEBARD GEORGE 0.10%  (43237) EBIX / ENZN / TPB /
LEBUHN ROBERT 0.10%  (42189) ENZN /
Greenberger Lee M VP, Research 0.08%  (36146) ENZN /
Deuel Thomas 0.07%  (32231) ENZN /
Young Richard A 0.07%  (30231) ENZN /
Daly Timothy VP, Controller and PAO 0.02%  (8000) ENZN / OVID /
Ogden Mark L Acting VP of Fin & Prin FO 0.01%  (4000) ENZN /